title: VLDL metabolism in rats is affected by the concentration and source of dietary protein.
abstract: The present study was designed to determine if changes in dietary protein level and source are related to changes in VLDL lipid concentrations and VLDL binding by hepatic membranes and isolated hepatocytes. Male Wistar rats were fed cholesterol-free diets containing 10, 20 or 30 g/100 g casein or highly purified soybean protein for 4 wk. Hepatic, plasma and VLDL lipids, VLDL apo B-100 and VLDL uptake by isolated hepatocytes and VLDL binding to hepatic membrane were determined. Increasing casein or soybean protein level (from 10 to 30 g/100 g) in the diet increased VLDL apo B-100, indicating an increase in the number of VLDL particles. VLDL uptake by isolated hepatocytes and VLDL binding to hepatic membrane increased when the protein level increased from 10 to 20 g/100 g in the diet and decreased with 30 g/100 g protein, regardless of protein type. The dietary protein source did not affect plasma total cholesterol concentrations at any protein level. Feeding 20 g/100 g soybean protein compared with casein lowered plasma triglyceride concentrations and VLDL number as measured by decreased VLDL-protein, -phospholipid, -triglyceride, -cholesterol and -apo B-100. VLDL uptake by isolated hepatocytes and VLDL binding to hepatic membrane were higher in rats fed soybean protein than those fed casein. The higher VLDL uptake could be responsible for the hypotriglyceridemia in rats fed soybean protein.
authors.affiliation: Unité de Nutrition Cellulaire et Métabolique, Faculté des Sciences Gabriel, Dijon, France.
authors.forename: Sihem
authors.initials: S
authors.lastname: Madani
authors.forename: Josiane
authors.initials: J
authors.lastname: Prost
authors.forename: Michel
authors.initials: M
authors.lastname: Narce
authors.forename: Jacques
authors.initials: J
authors.lastname: Belleville
mesh_terms: D000818:Animals; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000037:antagonists & inhibitors / Q000097:blood; D002364:Caseins / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D022781:Hepatocytes / Q000378:metabolism; D050356:Lipid Metabolism; D008079:Lipoproteins, VLDL / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D008566:Membranes / Q000378:metabolism; D009994:Osmolar Concentration; D051381:Rats; D017208:Rats, Wistar; D030262:Soybean Proteins / Q000008:administration & dosage*
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D002364:Caseins; D008079:Lipoproteins, VLDL; D030262:Soybean Proteins